Thermo Fisher Scientific Inc. (NYSE:TMO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

04 Apr 2026, 09:20 by Renee Jackson · The Cerbat Gem

Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, nineteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $632.50.

A number of research analysts have recently issued reports on TMO shares. KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a report on Sunday, December 7th. Evercore restated an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a report on Monday, January 5th. UBS Group reaffirmed a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. Robert W. Baird set a $653.00 target price on Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, TD Cowen cut their price objective on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a report on Friday, January 30th.

Get Our Latest Research Report on TMO

Insider Activity

In related news, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $541.20, for a total transaction of $216,480.00. Following the completion of the sale, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several large investors have recently made changes to their positions in the company. High Note Wealth LLC increased its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Swiss RE Ltd. acquired a new position in Thermo Fisher Scientific in the 4th quarter worth about $28,000. JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the third quarter valued at approximately $28,000. Highline Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 126.9% in the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock worth $29,000 after acquiring an additional 33 shares in the last quarter. Finally, Beacon Financial Strategies CORP purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $492.90 on Friday. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $643.99. The stock has a fifty day simple moving average of $516.40 and a two-hundred day simple moving average of $547.68. The stock has a market capitalization of $183.10 billion, a price-to-earnings ratio of 27.78, a P/E/G ratio of 2.63 and a beta of 0.97. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $6.10 EPS. On average, analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Friday, March 13th will be paid a $0.47 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.60%.

About Thermo Fisher Scientific

(Get Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.